No label defined (Q3304849)

From EU Knowledge Graph
Revision as of 17:52, 24 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy., translated_summary)
Jump to navigation Jump to search
Project Q3304849 in Germany
Language Label Description Also known as
English
No label defined
Project Q3304849 in Germany

    Statements

    country
    Germany
    0 references
    EU contribution
    656,244.0 Euro
    0 references
    budget
    820,305.0 Euro
    0 references
    co-financing rate
    80.0 percent
    0 references
    start time
    28 September 2017
    0 references
    end time
    30 June 2023
    0 references
    beneficiary name (string)
    Miltenyi Biotec GmbH Niederlassung Teterow
    0 references
    postal code
    17166 - Teterow
    0 references
    summary
    Entwicklung einer Vorhersagemöglichkeit für den Nutzen der Apherese bei Multiple Sklerose (MS) Patienten im akuten Schub. Dazu werden diagnostische Kits entwickelt, die Responder von Non-Respondern für die Plamapherese-Therapie unterscheiden. (German)
    0 references
    Development of a prediction for the benefit of apheresis in multiple sclerosis (MS) patients in acute thrust. For this purpose, diagnostic kits are developed that distinguish responders from non-responders for plamapheresis therapy. (English)
    point in time
    24 October 2021
    0 references

    Identifiers

    German Kohesio ID
    DE_TEMPORARY_7634
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3304849&oldid=13391950"